NURL — Neural Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$2.66m
- CA$2.41m
Annual cashflow statement for Neural Therapeutics, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -1.82 | -1.08 | -0.666 |
| Non-Cash Items | 1.08 | -0.011 | 0.047 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.141 | 0.56 | 0.299 |
| Change in Accounts Receivable | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Payable / Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -0.602 | -0.527 | -0.32 |
| Financing Cash Flow Items | 0.181 | 0 | -0.013 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 0.973 | 0.428 | 0.113 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 0.372 | -0.099 | -0.207 |